New and Emerging Therapies in Psoriasis

被引：0
|
作者：
Leonardi, Craig L. [1 ,2 ]
Gordon, Kenneth B. [3 ]
机构：
[1] St Louis Univ, St Louis, MO 63103 USA
[2] Cent Dermatol, St Louis, MO 63117 USA
[3] Northwestern Univ, Feinberg Sch Med, Chicago, IL USA
来源：
SEMINARS IN CUTANEOUS MEDICINE AND SURGERY | 2014年 / 33卷
关键词：
Apremilast; brodalumab; interleukin-12/23; inhibitors; interleukin-17; ixekizumab; JAK; Janus kinase inhibitors; phosphodiesterase-4; psoriasis treatment; secukinumab; tildrakizumab; tofacitinib; tumor necrosis factor inhibitors; ustekinumab; INTERLEUKIN-12/23; MONOCLONAL-ANTIBODY; CHRONIC PLAQUE PSORIASIS; TO-SEVERE PSORIASIS; DOUBLE-BLIND; USTEKINUMAB; SAFETY; EFFICACY; TRIAL;
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
This article discusses the scientific rationale for the use of cytokine inhibitors, including ustekinumab, an inhibitor of the interleukin (IL)-12 and IL-23 pathways in psoriasis. Also addressed are the efficacy and safety data for this agent, as well as for several emerging therapies that target other cytokine pathways in psoriasis: the IL-17 inhibitors secukinumab, ixekizumab, and brodalumab, the IL-23 blacker tildrakizumab, and the small-molecule kinase inhibitors apremilast (a phosphodiesterase-4 blacker) and tofacitinib (a Janus kinase inhibitor). (C) 2014 published by Frontline Medical Communications
引用
收藏
页码：S37 / S41
页数：5
相关论文
共 50 条
  • [41] Oral Psoriasis Therapies
    James, Jabreia
    Otto, Tracey
    Gao, Julia
    Porter, Martina L.
    DERMATOLOGIC CLINICS, 2024, 42 (03) : 357 - 363
  • [42] Biologic Therapies for Psoriasis
    de Felice, Catia
    Ardigo, Marco
    Berardesca, Enzo
    JOURNAL OF RHEUMATOLOGY, 2009, 36 : 62 - 64
  • [43] Biological therapies for psoriasis
    Mansouri, Bobbak
    Patel, Mahir
    Menter, Alan
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2013, 13 (12) : 1715 - 1730
  • [44] Therapeutic Advances in Psoriasis: From Biologics to Emerging Oral Small Molecules
    Ferrara, Francesco
    Verduci, Chiara
    Laconi, Emanuela
    Mangione, Andrea
    Dondi, Chiara
    Del Vecchio, Marta
    Carlevatti, Veronica
    Zovi, Andrea
    Capuozzo, Maurizio
    Langella, Roberto
    ANTIBODIES, 2024, 13 (03)
  • [45] The role of IL 23 in the treatment of psoriasis
    Puig, Lluis
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2017, 13 (06) : 525 - 534
  • [46] Brodalumab in the treatment of chronic plaque psoriasis
    Gisondi, Paolo
    Girolomoni, Giampiero
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2020, 20 (10) : 1175 - 1185
  • [47] Anti IL-17 in psoriasis
    Ly, Karen
    Smith, Mary P.
    Thibodeaux, Quinn
    Reddy, Vidhatha
    Liao, Wilson
    Bhutani, Tina
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2019, 15 (11) : 1185 - 1194
  • [48] A Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque Psoriasis
    Campa, Molly
    Mansouri, Bobbak
    Warren, Richard
    Menter, Alan
    DERMATOLOGY AND THERAPY, 2016, 6 (01) : 1 - 12
  • [49] Small Molecules and Biologics in the Treatment of Nail Psoriasis
    Rigopoulos, Dimitrios
    Stathopoulou, Anna
    Gregoriou, Stamatios
    SKIN APPENDAGE DISORDERS, 2020, 6 (03): : 134 - 141
  • [50] Review of IL-17 inhibitors for psoriasis
    Amin, Mina
    Darji, Kavita
    No, Daniel J.
    Bhutani, Tina
    Wu, Jashin J.
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2018, 29 (04) : 347 - 352
12345